乏精子症に対するmethylcobalamin大量療法の有用性に関する研究

Abstract

乏精子症例39例に対して, CH3-B12を1日あたり6 mg, ないし12 mgの投与による治療を試みた.1) CH3-B12大量投与による血清中, 精漿中総V-B12濃度の上昇は, 6 mg投与群, 12 mg投与群において有意差を認めなかった.2) CH3-B12は精漿中への移行が良好なことが示唆された.またこの移行は6 mg投与群, 12 mg投与群において有意差を認めなかった.3) CH3-B12大量療法の有効率は6 mg投与群では37.5%, 12 mg投与群では39.1%であり, 乏精子症に対する有用な治療法であると考えられた.なお両群間の有効率に有意差を認めないことより, 投与量としては6 mgが適当であると考えられた.4) CH3-B12大量投与において重篤な副作用の出現はみられなかった

Methylcobalamin (CH3-B12) was administrated in a dose of 6 mg per day (group A, 16 cases) or 12 mg per day (group B, 23 cases) for 16 weeks to patients with oligozoospermia. There was no difference between group A and group B regarding vitamin B12 concentrations in the serum or seminal fluid. CH3-B12 appeared to be transported to seminal fluid very efficiently. However, results from group A and group B did not differ with respect to this parameter. The efficacy rate for group A was 37.5% and that for group B was 39.1%. From these results, it was concluded that a long-term, high dose treatment of CH3-B12 was useful for the treatment of patients with oligozoospermia. Since the efficacy rates were not different between the two groups, 6 mg per day would be the recommended dose. Clinical adverse reactions were observed in one patient in each group. Drug-related laboratory adverse reactions were observed in only one patient in group B.